Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Correction to: Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin

Correction to: Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and... PharmacoEconomics (2018) 36:881 https://doi.org/10.1007/s40273-018-0676-8 CORRECTION Correction to: Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin 1 2 Guy Neff Woodie Zachry III Published online: 1 June 2018 The Author(s) 2018 Correction to: PharmacoEconomics https://doi.org/10.1007/s40273-018-0641-6 The article Systematic Review of the Economic Burden of distribution and reproduction in any medium or format, as Overt Hepatic Encephalopathy and Pharmacoeconomic long as you give appropriate credit to the original Impact of Rifaximin written by Guy Neff, Woodie Zachry author(s) and the source, a link is provided to the Creative was originally published electronically on the publisher’s Commons license and any changes made are indicated. internet portal (currently Springer Link) on April 12, 2018 Open Access This article is distributed under the terms of without open access. the Creative Commons Attribution-Non Commercial 4.0 With the author(s)’ decision to opt for Open Choice the International License (http://creativecommons.org/ copyright of the article changed on May 31, 2018 to  The licenses/by-nc/4.0/), which permits any non commercial Author(s) [2018] and the article is forthwith distributed use, distribution, and reproduction in any medium, pro- under the terms of the Creative Commons Attribution- Non vided you give appropriate credit to the original Commercial 4.0 International License (http:// author(s) and the source, provide a link to the Creative creativecommons.org/licenses/by-nc/4.0/), which permits Commons license, and indicate if changes were made. any noncommercial use, duplication, adaptation, The original article can be found online at https://doi.org/10.1007/ s40273-018-0641-6. & Guy Neff guy.neff@fdhs.com Florida Research Institute, Florida Digestive Health Specialists, Lakewood Ranch, FL, USA Quantym Therapeutic Data, Sarasota, FL, USA http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics Springer Journals

Correction to: Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin

Neff, Guy; Zachry, Woodie
PharmacoEconomics , Volume 36 (7) – Jun 1, 2018
Download PDF
1 page

Loading next page...
 
/lp/springer_journal/correction-to-systematic-review-of-the-economic-burden-of-overt-kOdvhEvFOn
Publisher
Springer Journals
Copyright
Copyright © 2018 by The Author(s)
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Health Administration; Public Health
ISSN
1170-7690
eISSN
1179-2027
DOI
10.1007/s40273-018-0676-8
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics (2018) 36:881 https://doi.org/10.1007/s40273-018-0676-8 CORRECTION Correction to: Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin 1 2 Guy Neff Woodie Zachry III Published online: 1 June 2018 The Author(s) 2018 Correction to: PharmacoEconomics https://doi.org/10.1007/s40273-018-0641-6 The article Systematic Review of the Economic Burden of distribution and reproduction in any medium or format, as Overt Hepatic Encephalopathy and Pharmacoeconomic long as you give appropriate credit to the original Impact of Rifaximin written by Guy Neff, Woodie Zachry author(s) and the source, a link is provided to the Creative was originally published electronically on the publisher’s Commons license and any changes made are indicated. internet portal (currently Springer Link) on April 12, 2018 Open Access This article is distributed under the terms of without open access. the Creative Commons Attribution-Non Commercial 4.0 With the author(s)’ decision to opt for Open Choice the International License (http://creativecommons.org/ copyright of the article changed on May 31, 2018 to  The licenses/by-nc/4.0/), which permits any non commercial Author(s) [2018] and the article is forthwith distributed use, distribution, and reproduction in any medium, pro- under the terms of the Creative Commons Attribution- Non vided you give appropriate credit to the original Commercial 4.0 International License (http:// author(s) and the source, provide a link to the Creative creativecommons.org/licenses/by-nc/4.0/), which permits Commons license, and indicate if changes were made. any noncommercial use, duplication, adaptation, The original article can be found online at https://doi.org/10.1007/ s40273-018-0641-6. & Guy Neff guy.neff@fdhs.com Florida Research Institute, Florida Digestive Health Specialists, Lakewood Ranch, FL, USA Quantym Therapeutic Data, Sarasota, FL, USA

Journal

PharmacoEconomics – Springer Journals

Published: Jun 1, 2018

There are no references for this article.